Hybrid Immunoglobulins TRIZ Cases

Ectopic functional ADAM6 restores male fertility in immunoglobulin-modified mice while preserving diverse human antibody repertoires.

Ectopic ADAM6 restores male fertility in humanized antibody mice while preserving diverse human immunoglobulin production.

Engineered anti-Sclerostin antibody constructs improve binding affinity and promote bone formation for osteoporosis and fracture treatment.

Complementary charge pairs and tuned anti-CD3 affinity improve bispecific antibody purity while reducing cytokine storm and off-target FcγR effects.

Affinity-matured scFv antibodies improve TAG-72 binding and T-cell engagement to better destroy TAG-72-expressing cancer cells.

Charged hinge and CH3 mutations use electrostatic pairing to boost bispecific antibody heterodimer yield and purity while limiting homodimers.

A bispecific afucosylated antibody targets ERBB-2 and ERBB-3 to limit tumor escape and resistance in high receptor-ratio tumors.

Site-specific cysteine mutation enables stable disulfide-linked IgG dimers while reducing heterogeneity and unwanted oligomer formation.

A humanized IgH locus replaces chicken V-D-J regions to enable V(D)J recombination and broader human-like antibody diversity.

A 3D tetrahedral antibody uses non-peptidyl linkages to position Fab and Fc domains for simultaneous binding to multiple targets.

Specific binding tags and cleavable domains guide correct chain pairing, reducing unwanted antibody combinations in bispecific protein production.

Binding two HER2 epitopes drives rapid endocytosis and lysosomal degradation, extending ADC killing to HER2-low tumors with lower cardiotoxicity.

Selective IL-2Rβ binding plus PEG-Fc extension sustains immune activation while reducing toxicity, side effects, and dosing frequency.

Smaller ROR1-binding single-domain antibodies improve tissue penetration and stability while supporting cancer imaging, diagnosis, and treatment.

Targeting APRIL and Blys with TACI-Fc dosing reduces urine protein and improves kidney function in membranous nephropathy.

A dual-binding antibody targets FGFR2-positive tumor cells and blocks PD-1 suppression to combine ADCC killing with restored T-cell activity.

Specific CH3 amino acid substitutions favor heavy-chain heterodimers over homodimers, improving bispecific antibody yield and reducing mispairing.

Differential light-chain affinity enables rapid isolation of bispecific antibodies from homodimers, improving purity without complex purification.

Selective anti-TGFβ3 antibodies block TGFBR2 binding to curb fibrotic signaling while avoiding the toxicity seen with pan-TGFβ inhibitors.

Adenosine-dependent anti-CTLA-4 Fc variants boost tumor-site ADCC, CDC, and ADCP while limiting autoimmune effects in normal tissues.

Lowering CD3 binding affinity curbs cytokine release while preserving PBMC-mediated tumor killing and reducing off-target toxicity.

Chimeric hinge and Fc constant domain engineering reduces Fc receptor binding and cuts ADCC, ADCP, CDC, and cytotoxicity in therapeutic antibodies.

Imbalanced binding affinities let one antibody arm strongly target a first antigen while the other selectively engages a second for better killing.

Dual TIM-3 and CD39 binding helps overcome low checkpoint inhibitor response by boosting T-cell activity and cancer-cell cytotoxicity.

EpCAM-targeted immune cells address weak solid-tumor CAR-T response by recognizing and killing metastatic EpCAM-expressing cells.

NKp46-binding variable regions redirect NK cells to lyse target cells, enabling a defined alternative to CD3-linked bispecific antibodies.

A sandwiched GPRC5D-CD3 bispecific antibody recruits T cells to tumors while limiting non-specific cytokine release in multiple myeloma.

Dual-affinity CD47 and PD-L1 binding improves tumor selectivity, limits healthy-cell toxicity, and supports stronger antitumor killing.

Orthogonal CH3 mutations use knob-in-hole, cascade, and charge-pair interfaces to favor antibody heterodimers over homodimers.

By linking BCMA targeting with 4-1BB activation, this case shows a myeloma antibody approach that boosts immune killing while limiting liver toxicity.

Weak CD3 binding enables bispecific antibodies to sustain tumor-directed T cell killing while reducing toxicity and improving pharmacokinetics.

Bird-derived variable regions paired with human regions enable stable, cross-reactive antibodies that bind novel human antigen epitopes.

Novel anti-TIM-3 antibodies use agonistic immune-cell activation to improve cancer immunotherapy where efficacy and mechanism clarity are limited.

Aglycosylated HER2-CD3 bispecific antibodies redirect T cells to HER2-positive tumors while avoiding Fc receptor activation and anti-mouse responses.

Dual CD38 and CD47 targeting with tuned binding affinity broadens the therapeutic window and helps limit toxicity in refractory myeloma.

Engineered mice replace heavy-chain variable segments with VL and JL genes to generate diverse, high-affinity antigen-binding proteins.

Bispecific MUC16-CD3 binding directs T cells to MUC16-expressing tumors, improving targeted killing where conventional anti-MUC16 therapies fall short.

By binding tumor antigens and CD3, CD28, or CD137, trispecific antibodies boost T-cell killing while limiting damage to normal cells.

An asymmetric monovalent-bivalent antibody format improves HER2 tumor selectivity while limiting on-target, off-tumor toxicity.

Aglycosylated HER2-CD3 bispecific antibodies recruit T cells to kill low-HER2 cancers, including cases resistant to PD-L1 and PD-1 blockade.

Transferrin-linked solanezumab scFv uses receptor-mediated uptake and cleavable release to cross brain, eye, and tumor barriers.

Multispecific antigen-binding proteins use dual HLA-peptide and CD3 targeting to improve tumor cell killing while limiting off-target binding.

Specific Fc mutations remove Fcγ receptor and complement interactions, reducing thrombotic risk while preserving CD40L blocking activity.

Dual EGFR and c-Met binding blocks HGF/c-Met signaling to inhibit tumor growth, invasion, and migration in EGFR-TKI resistant tumors.

Fc-engineered anti-CTLA-4 antibodies tune binding by ATP, ADP, or AMP levels to preserve antitumor immunity while limiting autoimmune side effects.

Targeting DLL3, MUC17, or CLDN18.2 while activating CD3, CD28, and CD137 helps T-cells kill cancer cells with fewer effects on normal cells.

Intein-mediated tag coupling links different components onto paired monomers to produce natural-sequence bispecific heterodimers with fewer unwanted combinations.

A dual-Fc antibody architecture boosts Fcγ receptor affinity and effector function while avoiding the size and heterogeneity of tandem Fc formats.

Transferrin receptor-mediated uptake helps semorinemab scFv cross brain and eye barriers, then release inside target cells via cleavable linkers.

Dual CD20-PD1 binders suppress autoreactive T and B cells to reduce autoimmune responses while avoiding broad immunosuppressive side effects.

A monoclonal antibody to the SPARC N-terminus enables sensitive biofluid testing to distinguish lung cancer from IPF and track disease progression.

Hinge-region Fc mutations reduce Fc receptor binding and unwanted ADCC or ADCP, improving antibody safety when cytotoxicity is not desired.